GPC3在卵巢癌中的表达及其临床意义

Expression of glypican-3 in ovarian carcinoma and its clinical significance

目的探讨GPC3在卵巢癌中的表达及其临床意义。方法利用实时荧光定量RT-PCR技术检测2004年1月-2005年10月手术获得的35例卵巢上皮性癌组织及23例正常卵巢组织中GPC3 mRNA的表达量，并结合卵巢癌的临床病理特点进行分析。利用Western blot技术检测4例卵巢癌组织和3例正常卵巢组织中GPC3蛋白的表达水平。结果GPC3 mRNA在卵巢癌组织中的表达量低于正常卵巢组织（P〈0.05），部分卵巢癌组织无GPC3 mRNA表达。GPC3 mRNA的表达量与卵巢癌临床分期有关，在Ⅲ、Ⅳ期卵巢癌组织中的表达量显著低于Ⅰ、Ⅱ期（P〈0.05）。GPC3 mRNA与CA125在卵巢癌中的表达无相关性（P〉0.05）。GPC3蛋白在正常卵巢组织中的表达水平是卵巢癌组织中的2-3倍。结论GPC3在卵巢癌的发生发展中起着一定作用，其与CA125联合应用有可能提高卵巢癌的阳性诊断率。

Objective To study the expression of GPC3 mRNA and GPC3 protein in ovarian carcinoma, and to investigate the clinical significance of their expression. Methods 35 specimens of ovarian carcinomas and 23 specimens of normal ovarian tissues were obtained from the patients undergoing operation during Jan. 2004 to Oct. 2005. The expressions of GPC3 mRNA in ovarian carcinomas and normal ovarian tissues were detected by real-time fluorescence quantitative PCR （RT PCR）. The clinical and pathological characteristics of ovarian carcinomas were analyzed. The expression of GPC2 protein was detected in 4 specimens of ovarian carcinomas and 3 specimens of normal ovarian tissues by Western bloting. Results The expression level of GPC3 mRNA in ovarian carcinomatous was down-regulated compared with that in normal ovarian tissues （P〈0. 05）. No expression of GPC3 mRNA was found in some of ovarian carcinomas tissues. The expression level of GPC3 mRNA was closely correlated with the FIGO clinical stage of ovarian carcinomas. The expression level in FIGO clinical stage Ⅲ and Ⅳ was lower than that inⅠandⅡstage （P〈0. 05）. No correlation existed between the expression level of GPC3 mRNA in ovarian carcinomas with age, tumor differentiation and pathological types. Also there was no correlation between GPC3 mRNA and CA125 values in ovarian carcinomas （P〉0. 05）. The expression of GPC3 protein was consistent with the expression of GPC3 mRNA. GPC3 pro tein was doubly or trebly expressed in normal ovarian tissues compared with ovarian carcinomas. Conclusion The present study suggests that GPC3 may be related to the occurrence and development of the ovarian carcinoma. The simultaneous determination of GPC3 and CA125 may increase the sensitivity of diagnosis for ovarian carcinoma.